SAVA stock reverses gains as journal retracts Alzheimer's paper (NASDAQ:SAVA)
seekingalpha.com
finance
2022-06-01 17:25:33

selvanegra/iStock via Getty Images Following a sharp rise on Tuesday, Alzheimer's drug developer Cassava Sciences (NASDAQ:SAVA) is currently on a steep decline after science publication SpringerLink retracted an article co-authored by the company's key collaborator, Dr. Hoau-Yan Wang. The paper, first published in 2017, discussed a genetic factor for late-onset Alzheimer's disease using a mouse model. Editors of the publication have retracted the article citing concerns over certain western blot images.
